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Despite recent advances in therapy, pulmonary arterial hypertension (PAH), characterized by 
occlusive vasculopathy of the pulmonary arteries, remains a progressive disease without a cure 
(1-3). While the currently approved PAH medications haven’t demonstrated anti-remodeling 
properties in humans, novel anti-proliferative strategies have shown some benefits but also raised 
safety concerns (4-6), none target a genetic predisposition of PAH, the dysfunctional Bone 
Morphogenetic Protein Receptor 2 (BMPR2) signaling.  
Loss-of-function mutations in BMPR2 in familial and idiopathic (I)PAH patients (7-9) are 
associated with increased pulmonary vasculopathy (10). Furthermore, reduced BMPR2 
expression is observed even in patients without a mutation, reinforcing the importance of 
decreased BMPR2 in PAH (11). In a high throughput screen of 3,600 FDA approved drugs we 
identified low-dose FK506 (tacrolimus) as a potent BMPR2 activator that reversed experimental 
PAH (12). We therefore hypothesized that low dose FK506 would be beneficial in PAH patients 
by increasing BMPR2 signaling.  
Based on these findings, we initiated a randomized, double-blind, placebo-controlled phase IIa 
trial (TraNsFORM, NCT#01647945) to evaluate the safety and tolerability of FK506 in stable 
PAH patients. Here, we report our clinical experience with compassionate use of low-dose 
FK506 in three end-stage PAH patients who did not qualify for TraNsFORM due to severity of 
illness (patient details in supplement). We assessed traditional clinical parameters, New York 
Heart Association (NYHA) functional class, six-minute walk distance (6MWD), serologic 
biomarkers, hospital admissions as well as protocolized cardiac magnetic resonance imaging 
(cMRI) assessed by blinded readers (13, 14). All patients remained on stable doses of PAH 
medication and diuretics throughout the 12-months period.  
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Patient #1: 36-year-old historically athletic female, NYHA-IV with rapidly progressive IPAH 
requiring rapid up-titration of epoprostenol, and addition of sildenafil and ambrisentan for 
recurrent hospitalizations for RV failure (Table 1). Despite aggressive treatment, she still 
reported NYHA-III/IV symptoms, an elevated N-terminal-pro-B type natriuretic peptide (NT-
proBNP) and a REVEAL risk score of 11, stratifying her as high risk with a potential 1-year 
mortality of 15-30% (3, 15), she was listed for lung transplantation. At that time she was offered 
compassionate treatment with FK506 (goal trough blood level 1.5-2.5 ng/mL).  
Within 1 month of FK506 initiation, she reported substantial improvement in symptoms (Figure 
1). Within 2 months she was placed on hold for transplantation by the lung transplant team. After 
3 months, her 6MWD distance improved by 100 meters, her NT-proBNP decreased >50% and 
she reported NYHA-I symptoms (Figure S1A, Table 1). Over the 12-month period, cMRI 
showed a stable RV ejection fraction (RVEF), RV end-diastolic volume index (RVEDVi), and 
cardiac index (CI) (Figure S1B). Her REVEAL risk score decreased to 3 (range 3-6), placing her 
in the low risk category (Table 1). While the 12 months prior to FK506 were characterized by 3 
hospitalizations for RV failure, the subsequent 12 months were free of any PAH associated 
hospitalizations (Table 1). At the time of this submission, the patient is 27 months from the 
initiation of FK506, continues to report NYHA-II symptoms, and has been free from 
hospitalization or clinical deterioration. 
Patient #2: 50-year-old female with end-stage systemic sclerosis associated PAH on intravenous 
treprostinil, sildenafil, ambrisentan, as well as an intravenous dopamine infusion for end-stage 
RV failure and hypotension. Patient continued to report NYHA-III/IV symptoms, had an 
elevated NT-pro BNP (range 4,926–15,161 pg/mL) and 4 hospitalizations for progressive RV 
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failure and palliative paracenteses (Table 1). Given the lack of further therapeutic options, she 
was offered FK506.  
cMRI at baseline, 3 and 6 months showed substantial improvement in RVEF, stable RVEDVi 
and improvement in RVSVi and CI (Figure S1B), with a reduction back to baseline at 12 
months.  Her REVEAL risk score decreased from 12 to 11. At 12-month follow-up, she had 
stable NYHA-III symptoms, a 94-meter increase in 6MWD, 30% reduction in her NT-proBNP 
and no PAH related hospitalizations since being on FK506 (Table 1). Patient is currently 26 
months post FK506 initiation and has not experienced further clinical deterioration. 
Patient #3: 55-year-old female with severe end-stage drugs-and-toxins-associated PAH, NYHA-
III/IV, on high dose IV treprostinil, sildenafil, intolerance to ERAs, listed for lung 
transplantation was offered FK506. Despite initial symptomatic improvement (Table 1), patient 
voluntarily discontinued FK506 after 4.5 months. Unfortunately, over the ensuing 7 months, she 
showed progressive clinical worsening, culminating in a ICU admission for RV failure and large 
pericardial effusion. Upon the patient’s wish, she was restarted on FK506 and is currently 12 
months post her second FK506 initiation, feeling much better with compensated NYHA-II 
symptoms and without any further hospital admission for RV failure. 
Serologic Biomarkers:  
None of the three patients had mutations in BMPR2, SMAD9 or caveolin-1. We measured 
BMPR2 expression and specific BMPR2 associated genes and molecules (Id1, Smurf-1, IL-6, 
LIMK1, Cofilin-1, miRNAs 21 and 27a) at baseline, 3, 6 and 12 months FK506 treatment in 
patients versus healthy controls (n=12) (see supplement). Patients had significantly lower 
BMPR2 mRNA expression at baseline (Figure 1) with near normalization of BMPR2 and 
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associated genes after 12 months of FK506 treatment. Strikingly, Patient #3 who stopped FK506 
after 4.5 months and who worsened clinically over the following 7 months, showed a 12-months 
BMPR2 profile that was opposite to that of patients still on FK506 therapy.  
Discussion: 
Our results suggest potential clinical benefit of low dose FK506 in end-stage PAH, judged by the 
marked clinical response, stabilization in cardiac function and freedom from hospitalization for 
RV failure. Despite the overall positive experience, we caution that these findings are highly 
preliminary. The efficacy of this therapy must be validated in appropriate, well-designed, 
prospective clinical trials. Our choice of low-dose FK506 was based on data from pre-clinical 
studies (12) and the desire to avoid major immunosuppressive side effects in patients with 
indwelling lines. We did not observe an increase in line-sepsis or opportunistic infections. We 
also did not observe serious adverse effects of posterior reversible encephalopathy syndrome, 
acute kidney injury or worsening of creatinine, an elevated systemic blood pressure, 
hyperglycemia, hyperkalemia, anemia, or a change in white blood cell count, The currently 
underway-clinical phase IIa trial will address safety and tolerability in greater detail, as even 
low-dose immunosuppression over time can lead to complications.    
This is the first study in PAH patients that repurposes FK506 to increase BMPR2 signaling. The 
changes in serologic biomarkers are encouraging and show that we have indeed targeted BMPR2 
in patients with reduced levels of BMPR2. It will be of interest to determine whether the same 
effect can be achieved in patients with documented mutations and whether a subset of patients 
are particularly sensitive to the beneficial effects of this strategy and could therefore be identified 
up-front as potential “responders” – based on BMPR2 levels.  
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Figure Legends: 
 
Table 1: Timeline of symptoms, clinical parameters, events, and therapies for patients #1-3 
before and after initiation of FK506. REVEAL Risk Score %1-year survival: Score 1-7 = 95-
100% (low risk), 8 = 90-95% (average risk), 9 = 85-90% (moderately high risk), 10-11 = 70-85% 
(high risk), 12 or above = <70% (very high risk)(3). Events reported as those related to PAH: 
RVF= right ventricular failure, HepF = hepatic failure, Sync = syncope, Tx List = listed for heart 
and/or lung transplantation, Tx Hold = placed on hold for transplantation due to clinical 
improvement. Prost = prostacyclin, PDE-5I = phosphodiesterase-5 inhibitor, ERA = endothelin 
receptor antagonist, Dop = dopamine, NYHA = New York Heart Association functional class. 
Figure 1: Biomarkers for patients #1-3 before and after initiation of FK-506. (A) BMPR2 
mRNA/GAPDH in PBMCs of healthy controls at baseline (B) (n=12) and 3 patients (n=3) at 
baseline (B), 3 months (3) and 6 months (6) and 12 months (12). The red dotted line indicates the 
time FK506 was stopped in Patient #3. (B) Id1 /GAPDH mRNA in PBMCs. (C) SMURF-
1/GAPDH mRNA in PBMCs. (D) IL-6 plasma levels via ELISA. (E) LIMK1/GAPDH mRNA in 
PBMCs. (F) Cofilin-1/GAPDH mRNA in PBMCs. (G) and (H) respectively miR21/RNU48 and 
mir27a/RNU48 RNA expression in PBMCs, respectively. 
 
 
 
 
 
 
! )!
References 
1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N 
Engl J Med 2004;351:1425-1436. 
2. Galie N, Manes A, Negro L, Palazzini M, Bacchi-Reggiani ML, Branzi A. A meta-
analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 
2009;30:394-403. 
3. Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of 
long-term survival from time of diagnosis in pulmonary arterial hypertension from the reveal 
registry. Chest 2012;142:448-456. 
4. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai 
YJ, Weissmann N, Seeger W, Grimminger F. Reversal of experimental pulmonary hypertension 
by pdgf inhibition. Journal of Clinical Investigation 2005;115:2811-2821. 
5. Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, Gomez-Sanchez MA, 
Grimminger F, Grunig E, Hassoun PM, Morrell NW, Peacock AJ, Satoh T, Simonneau G, 
Tapson VF, Torres F, Lawrence D, Quinn DA, Ghofrani HA. Imatinib mesylate as add-on 
therapy for pulmonary arterial hypertension: Results of the randomized impres study. Circulation 
2013;127:1128-1138. 
6. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro 
S, Golpon H, Toshner M, Grimminger F, Pascoe S. Imatinib in pulmonary arterial hypertension 
patients with inadequate response to established therapy. Am J Respir Crit Care Med 
2010;182:1171-1177. 
7. Deng Z, Morse JH, Slager SL, Cuervo N, Moore KJ, Venetos G, Kalachikov S, Cayanis 
E, Fischer SG, Barst RJ, Hodge SE, Knowles JA. Familial primary pulmonary hypertension 
(gene pph1) is caused by mutations in the bone morphogenetic protein receptor-ii gene. Am J 
Hum Genet 2000;67:737-744. 
8. Machado RD, Aldred MA, James V, Harrison RE, Patel B, Schwalbe EC, Gruenig E, 
Janssen B, Koehler R, Seeger W, Eickelberg O, Olschewski H, Elliott CG, Glissmeyer E, 
Carlquist J, Kim M, Torbicki A, Fijalkowska A, Szewczyk G, Parma J, Abramowicz MJ, Galie 
N, Morisaki H, Kyotani S, Nakanishi N, Morisaki T, Humbert M, Simonneau G, Sitbon O, 
Soubrier F, Coulet F, Morrell NW, Trembath RC. Mutations of the tgf-beta type ii receptor 
bmpr2 in pulmonary arterial hypertension. Hum Mutat 2006;27:121-132. 
! ∗!
9. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, Ward 
K, Yacoub M, Mikhail G, Rogers P, Newman J, Wheeler L, Higenbottam T, Gibbs JS, Egan J, 
Crozier A, Peacock A, Allcock R, Corris P, Loyd JE, Trembath RC, Nichols WC. Sporadic 
primary pulmonary hypertension is associated with germline mutations of the gene encoding 
bmpr-ii, a receptor member of the tgf-beta family. J Med Genet 2000;37:741-745. 
10. Stacher E, Graham BB, Hunt JM, Gandjeva A, Groshong SD, McLaughlin VV, Jessup 
M, Grizzle WE, Aldred MA, Cool CD, Tuder RM. Modern age pathology of pulmonary arterial 
hypertension. Am J Respir Crit Care Med 2012;186:261-272. 
11. Atkinson C, Stewart S, Upton PD, Machado R, Thomson JR, Trembath RC, Morrell NW. 
Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of 
type ii bone morphogenetic protein receptor. Circulation 2002;105:1672-1678. 
12. Spiekerkoetter E, Tian X, Cai J, Hopper RK, Sudheendra D, Li CG, El-Bizri N, Sawada 
H, Haghighat R, Chan R, Haghighat L, de Jesus Perez V, Wang L, Reddy S, Zhao M, Bernstein 
D, Solow-Cordero DE, Beachy PA, Wandless TJ, Ten Dijke P, Rabinovitch M. Fk506 activates 
bmpr2, rescues endothelial dysfunction, and reverses pulmonary hypertension. J Clin Invest 
2013;123:3600-3613. 
13. Kind T, Mauritz GJ, Marcus JT, van de Veerdonk M, Westerhof N, Vonk-Noordegraaf 
A. Right ventricular ejection fraction is better reflected by transverse rather than longitudinal 
wall motion in pulmonary hypertension. J Cardiovasc Magn Reson 2010;12:35. 
14. Mauritz GJ, Kind T, Marcus JT, Bogaard HJ, van de Veerdonk M, Postmus PE, Boonstra 
A, Westerhof N, Vonk-Noordegraaf A. Progressive changes in right ventricular geometric 
shortening and long-term survival in pulmonary arterial hypertension. Chest 2012;141:935-943. 
15. Benza RL, Gomberg-Maitland M, Miller DP, Frost A, Frantz RP, Foreman AJ, Badesch 
DB, McGoon MD. The reveal registry risk score calculator in patients newly diagnosed with 
pulmonary arterial hypertension. Chest 2012;141:354-362. 
 
 
